Displaying drugs 10901 - 10925 of 11613 in total
Survodutide
Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)).
Investigational
Matched Description: … Survodutide is under investigation in clinical trial NCT06077864 (A Study to Test the Effect of Survodutide …
Mazdutide
Mazdutide is under investigation in clinical trial NCT06143956 (A Chronic Weight Management Master Protocol Study (LY900038) of Multiple Intervention-specific-appendices (Isas) in Adult Participants With Obesity or Overweight).
Investigational
Matched Description: … Mazdutide is under investigation in clinical trial NCT06143956 (A Chronic Weight Management Master Protocol …
Dazostinag
Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors).
Investigational
Matched Description: … Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent …
Pyroquilon
Pyroquilon is a commercial blasticide which binds in the naphthol pocket of fungal trihydroxynaphthalene reductase active site.
Experimental
Matched Description: … Pyroquilon is a commercial blasticide which binds in the naphthol pocket of fungal trihydroxynaphthalene …
Narnatumab
Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).
Investigational
Matched Description: … Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid …
TW-37
TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.
Investigational
Matched Description: … TW-37 is a small-molecule inhibitor of Bcl-2 investigated for its anti-cancer properties.[A253157] …
CGX-1321
CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling.
Investigational
Matched Description: … CGX-1321 is a porcupine inhibitor that affects Wnt production and can block Wnt downstream signaling. …
MEDI-491
MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins.
Investigational
Matched Description: … MEDI-491 is a recombinant human parvovirus B19 vaccine composed of the VP1 and VP2 capsid proteins. …
BHT-3034
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
Matched Description: … BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis …
RAG-17
RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase (SOD).
Investigational
Matched Description: … RAG-17 is a siRNA oligonucleotide designed to target and knockdown the expression of superoxide dismutase …
CEB-01
CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin
Investigational
Matched Description: … CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10 …
PARPI F-18
PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme.
Investigational
Matched Description: … PARPI F-18 is a diagnostic agent under investigation for use in the management of glioblastoma multiforme …
Fencamfamin
Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the...
Experimental
Illicit
Withdrawn
Matched Description: … Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite ... It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers …
LS11
LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. After intratumoral activation by light emitting diodes, taporfin sodium forms an extended high energy conformational state that generates singlet oxygen, resulting in free radical-mediated cell death. It is used to treat many...
Investigational
Encenicline
Encenicline has been investigated for the treatment of Cognition, Schizophrenia, Alzheimer's Disease, Cardiac Repolarization, and Central Nervous System Diseases.
Investigational
Motavizumab
Investigational
2,2':6',2''-Terpyridine Platinum(Ii)
2,2':6',2''-terpyridine Platinum(Ii) is a solid. Known drug targets of 2,2':6',2''-Terpyridine Platinum(Ii) include truncated transposase and autolysin.
Experimental
Matched Description: … 2,2':6',2''-terpyridine Platinum(Ii) is a solid. …
Veltuzumab
Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.
Investigational
Matched Description: … Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials …
Sarafloxacin
Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Vet approved
Withdrawn
Matched Description: … Sarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories …
Prasinezumab
Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease).
Investigational
Matched Description: … Prasinezumab is under investigation in clinical trial NCT03100149 (A Study to Evaluate the Efficacy of …
PF-04937319
PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects).
Investigational
Matched Description: … PF-04937319 is under investigation in clinical trial NCT01513928 (A Study To Compare The Pharmacokinetics …
BMS-791826
BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males).
Investigational
Matched Description: … BMS-791826 is under investigation in clinical trial NCT03198013 (A Study of Pharmacokinetics (PK) and …
PF-06650833
PF-06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects).
Investigational
Matched Description: … 06650833 is under investigation in clinical trial NCT02609139 (Study to Evaluate Pharmacokinetics of A …
RO-6870810
RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
Investigational
Matched Description: … RO-6870810 is under investigation in clinical trial NCT02308761 (A Study of RO6870810/TEN-010 in Participants …
Recombinant Super-Compound Interferon
Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified spatial configuration. This interferon has antiviral and antitumor activity.
Investigational
Matched Description: … Recombinant super-compound interferon (rSIFN-co) is a recombinant version of interferon alpha with modified …
Displaying drugs 10901 - 10925 of 11613 in total